Thermo Fisher Scientific Inc. the world leader in serving science, today published its 2020 Corporate Social Responsibility report, reflecting its commitment to society, stakeholders and environmental, social and governance efforts. The report provides detailed insight into the company's approach to CSR, outlines future priorities and highlights achievements across four pillars of focus: operations, colleagues, ...

- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today published its 2020 Corporate Social Responsibility (CSR) report, reflecting its commitment to society, stakeholders and environmental, social and governance (ESG) efforts. The report provides detailed insight into the company's approach to CSR, outlines future priorities and highlights achievements across four pillars of focus: operations, colleagues, communities and environment.

"Across Thermo Fisher Scientific, we hold ourselves accountable for doing business the right way and delivering on our responsibility to society," said Marc N. Casper , chairman, president and chief executive officer of Thermo Fisher Scientific. "From our mobilization to assist in the global response to the COVID-19 pandemic, our expanded D&I programs, our support of non-profit organizations and global health equity initiatives and our commitments to reduce greenhouse gas emissions, I'm proud to share all that our 90,000 colleagues accomplished in 2020."

Highlights from the company's 2020 CSR efforts include:

Operations

  • Mobilized significant resources and worked with speed at scale to accelerate the development, manufacturing and distribution of critical products and services in support of the societal response to the pandemic including more than 700 million PCR-based COVID-19 tests
  • Drove opportunity and equity through our world-class supply chain with $1.3 billion spent with businesses owned by women, minorities, veterans and members of the disabled and LGBTQ communities

Colleagues

  • Enhanced programming to support the company's more than 90,000 colleagues with robust training, talent development opportunities and increased retention efforts including a special pandemic response compensation structure
  • Advanced progress towards diversity and inclusion priorities and disclosures, with women comprising 40% of all global leadership hires

Communities

  • Invested $30 million to establish the Foundation for Science with a focus on enabling STEM education access for underserved groups and supported more than 2,900 not-for-profits through our global network of colleagues
  • In addition to a $25 million COVID-19 testing program to enable the safe reopening of historically black colleges and universities in the U.S., we partnered with global health organizations to ensure that more than 100 low- and middle-income countries had access to critical pandemic response supplies

Environment

  • Made progress on the company's 2050 net-zero goal and 2030 target to reduce greenhouse gas emissions across operations by 30% (from 2018 levels) and advancing our renewable energy strategy

Learn more about Thermo Fisher's commitment to CSR and our progress here www.thermofisher.com/csr

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $35 billion . Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 90,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com .

Media Contact Information:
Ron O'Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com

Investor Contact Information:
Rafael Tejada
Phone:  781-622-1356
E-mail: rafael.tejada@thermofisher.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/thermo-fisher-scientific-publishes-2020-corporate-social-responsibility-report-301408115.html

SOURCE Thermo Fisher Scientific

News Provided by Canada Newswire via QuoteMedia

IDBS Polar Insight Brings Advanced Data Analytics and Visualization to BioPharma Lifecycle Management

IDBS, a Danaher (NYSE:DHR) operating company, announced Polar Insight, bringing new advanced data analytics and visualization tools to the Polar BioPharma Lifecycle Management (BPLM) platform.

Extracting valuable insights from process and quality data across the biopharmaceutical lifecycle is a time consuming and error prone process, requiring laborious manual work and multiple steps.

Keep reading... Show less

Medtronic receives Health Canada licence for GI Genius intelligent endoscopy module with artificial intelligence system for colonoscopy

Transformative AI System Enhances Colorectal Cancer Detection Capabilities

 Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT) — the global leader in medical technology — announced it has received a Health Canada licence for the GI Genius™ intelligent endoscopy module. GI Genius is a computer-aided detection (CADe) system that uses artificial intelligence (AI) to highlight regions of the colon suspected to have visual characteristics consistent with different types of mucosal abnormalities.

Keep reading... Show less
Beyond Medical Technologies Ramps Up COVID Mask Manufacturing in Response to New South Africa COVID Variant

Beyond Medical Technologies Ramps Up COVID Mask Manufacturing in Response to New South Africa COVID Variant

Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM4) ("Beyond Medical" or the "Company") is pleased to provide the following corporate update regarding its wholly-owned subsidiary Micron Technologies Inc. ("Micron Technologies").

Keep reading... Show less
Leveljump Q3 Earnings and Results; Record Quarterly Revenues

Leveljump Q3 Earnings and Results; Record Quarterly Revenues

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce today it has reported financial results for the third fiscal quarter ended September 30th, 2021. All amounts are expressed in Canadian dollars.

Financial and Operational Highlights

Keep reading... Show less

Thermo Fisher Scientific Confirms Detection of SARS-CoV-2 in Samples Containing the Omicron Variant with its TaqPath COVID-19 Tests

- Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today confirmed that its polymerase chain reaction (PCR) TaqPath COVID-19 Combo Kit *, and TaqPath COVID-19 CE-IVD RT-PCR Kit *, which test for the presence of SARS-CoV-2, are not impacted by the emerging B.1.1.529, or Omicron variant, enabling accurate test results.

The Omicron variant, which was designated a " variant of concern " by the World Health Organization (WHO), has more than 30 mutations in the spike protein alone. The WHO has reported that preliminary evidence suggests an increased risk of transmission compared to other variants of concern. This designation and information are leading to renewed travel restrictions and research to examine the variant's impact on efficacy of existing vaccines and tests. The WHO and European Centers for Disease Control have both reported that using S-gene target failure (SGTF) of the PCR assays as a proxy for the variant helped to identify Omicron. Cases of the variant were first identified in South Africa and have now been reported in at least a dozen countries around the world.

Keep reading... Show less
UPDATED - Leveljump Healthcare Corp. Announces 14.6% Minority Investment in Real Time Medical

UPDATED - Leveljump Healthcare Corp. Announces 14.6% Minority Investment in Real Time Medical

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce that, subject to regulatory approval, it has agreed to acquire an outstanding 14.6% minority equity interest in Real Time Medical Inc. ("RTM"), a private Ontario company, in exchange for 2,494,576 units (a "Unit") of Leveljump. Each Unit will be issued at a price of $0.66 per Unit with each Unit being comprised of three (3) Leveljump common shares at a deemed price of $0.22 per share and one (1) share purchase warrant of Leveljump, each warrant entitling the holder to acquire one additional common share of Leveljump at a price of $0.35 per common share on or before December 31, 2023.

The equity interest in RTM was acquired through a mini-tender offer to the shareholders of RTM dated November 1, 2021 whereby JUMP offered to acquire up to 19.9% of RTM in exchange for the Units. The holders of the RTM shares who have tendered are all accredited investors.

Keep reading... Show less

Top News

Related News